1 May 2026Vaccines, immunoglobulins and antisera
Meningococcal A+C+W135 vaccine
Meningococcal A+C+W135 vaccine guidance for outbreak control and high-risk travel in hyperendemic areas.
This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.
Indications
- Prevention of meningitis due to meningococci groups A, C, and W135 in mass immunisation campaigns during outbreaks due to meningococcus A, C, or W135.
- Prevention for travellers spending more than 1 month in hyperendemic areas.
Composition, forms, route of administration
- Inactivated bacterial polysaccharide vaccine.
- Powder for injection in multidose vial, to be dissolved with the entire vial of the diluent supplied by the manufacturer.
- For SC injection only.
Dose and vaccination schedule
- Child from 2 years and adult: 0.5 ml single dose.
Contra-indications, adverse effects, precautions
- Do not administer to patients with history of allergic reaction to a previous injection of meningococcal vaccine.
- Vaccination should be postponed in the event of severe acute febrile illness; minor infections are not contra-indications.
- May cause mild local reaction and mild fever.
- Do not mix with other vaccines in the same syringe.
- If administered simultaneously with EPI vaccines, use different syringes and injection sites.
- Pregnancy and breast-feeding: no contra-indication.
- Immunity develops 7 to 10 days after injection and lasts approximately 3 years.
Source
MSF Essential drugs practical guidelines (January 2026)
This page reproduces the structured reference information for this batch while leaving out the Storage and Remarks sections.
Rate this guide
Be the first to rate this guide.